Galectin-3C combination therapy for human cancer
First Claim
1. A pharmaceutical combination having therapeutic synergy comprising:
- an effective amount of galectin-3C and the proteasome inhibitor bortezomib.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
-
Citations
13 Claims
-
1. A pharmaceutical combination having therapeutic synergy comprising:
an effective amount of galectin-3C and the proteasome inhibitor bortezomib. - View Dependent Claims (2, 3)
-
4. A pharmaceutical combination having therapeutic synergy comprising
an effective amount of galectin-3C and bortezomib to overcome resistance to bortezomib, wherein the galectin-3C and bortezomib are administered separately or simultaneously.
- 7. A pharmaceutical combination having therapeutic synergy comprising an effective amount of galectin-3C and salinosporamide A or carfilzomib.
- 9. A pharmaceutical combination comprising an effective amount of galectin-3C and proteasome inhibitor bortezomib to synergistically inhibit angiogenesis.
-
10. A pharmaceutical combination comprising an effective amount of galectin-3C and a proteasome inhibitor that synergistically inhibit angiogenesis.
Specification